Filing summary
Entity and period: The supplied filing is Magenta Therapeutics, Inc.’s audited Form 10-K for the fiscal year ended December 31, 2018, filed March 19, 2019. This does not match the request metadata, which names Dianthus Therapeutics, Inc.; verify that this is the intended filing. “2018 Q4” is not the filing period, although quarterly results are disclosed.
Business context
Magenta was a clinical-stage biotechnology company developing medicines to improve stem-cell transplant and related gene and cell therapies. Its portfolio addressed cell expansion (MGTA-456 and E478), mobilization (MGTA-145), targeted conditioning (C100, C200 and C300), and post-transplant complications (G100). It had no approved products and no product-sales revenue.
Financial results and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $41.3 million | $27.9 million |
| General and administrative expense | $18.6 million | $7.8 million |
| Operating loss | $60.0 million | $35.7 million |
| Net loss | $57.5 million | $35.5 million |
| Net loss per share, basic and diluted | $3.13 | $19.12 |
| Cash used in operating activities | $41.9 million | $22.3 million |
For Q4 2018, the filing reports an operating loss of $17.9 million and net loss of $16.7 million; quarterly revenue was zero. Profit margins are not meaningful because the company had no revenue and reported losses.
- At December 31, 2018, cash and cash equivalents were $58.3 million and marketable securities were $84.2 million, totaling $142.6 million. Working capital was $134.9 million.
- Total liabilities were $11.7 million; the filing shows no outstanding debt balance. Preferred stock converted to common stock upon the June 2018 IPO.
- Operating cash use increased from 2017. Investing cash use was $91.7 million, primarily reflecting $84.0 million of marketable-security purchases and $7.7 million of property and equipment purchases.
- The IPO raised approximately $89.9 million net; the company also received $52.2 million net from its Series C preferred financing. Stock-based compensation rose to $10.7 million from $2.3 million.
Material changes and operating developments
- Operating expenses increased by $24.2 million year over year, with R&D up $13.4 million and G&A up $10.8 million. Increased clinical, preclinical, staffing, public-company and facility costs contributed; lower expansion-program expense partly reflected the prior-year $9.3 million noncash MGTA-456 license cost.
- Cash, cash equivalents and marketable securities increased from $51.4 million at year-end 2017 to $142.6 million at year-end 2018, largely following financing activity, including the IPO.
- MGTA-456 was in a Phase 2 study for inherited metabolic disorders; an investigator-initiated Phase 2 blood-cancer study began in December 2018. MGTA-145 had not yet entered clinical testing at year-end.
- The company reported a $57.5 million accumulated net loss for 2018 and an accumulated deficit of $102.7 million at year-end.
Outlook, risks and unusual items
- Management expected expenses and losses to rise as development advanced. It estimated that year-end cash, cash equivalents and marketable securities would fund operating and capital needs through 2020, while cautioning that assumptions could prove wrong. The financial-statement note also states funding was expected to cover at least 12 months from issuance; additional capital would be needed thereafter.
- Planned milestones included starting a Phase 1 MGTA-145 trial in the first half of 2019, nominating a C100 development candidate in 2019, filing an IND for C200 in 2020, and potentially starting a Phase 3 MGTA-456 trial in 2020 if Phase 2 results were favorable. These are forward-looking plans, not guarantees.
- In the MGTA-456 inherited-metabolic-disorder study, early results in five patients showed successful engraftment and disease-marker observations. Autoimmune cytopenias occurred in young patients; the filing states these were considered unrelated to MGTA-456 and describes a study-enrollment focus on patients older than two. It also discloses that the first Phase 2 patient later died from an autoimmune cytopenia considered related to transplant complications, not specifically to MGTA-456.
- Major risks include clinical failure or delays, transplant-related safety events, regulatory uncertainty, dependence on third-party manufacturers and clinical providers, manufacturing contamination or supply interruption, financing needs, competition, reimbursement uncertainty, and reliance on licensed intellectual property. The company reported prior MGTA-456 manufacturing contamination before licensing, but no such event since licensing through the filing date.
- Contractual commitments included $56.4 million of operating lease payments, mainly for Cambridge space through February 2028, and a $1.8 million restricted-cash balance supporting a letter of credit. Additional milestone and royalty obligations under licenses are contingent on future events and sales.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. KPMG issued an unqualified audit opinion on the financial statements.
Most important facts to verify
- Confirm the issuer and period: the filing is Magenta Therapeutics’ FY 2018 10-K, not a Dianthus Therapeutics filing or a quarterly report.
- Check subsequent cash burn and financing against the stated runway through 2020, and reconcile that outlook with the financial-statement note’s 12-month funding statement.
- Review updated MGTA-456 safety, enrollment and efficacy disclosures, including the cytopenias, the disclosed patient death, and the enrollment-age change.
- Track whether planned clinical and regulatory milestones occurred, particularly MGTA-145’s trial start and C200’s IND filing.
- Assess reliance on single or limited third-party manufacturing sources, lease obligations, and potential license milestones, royalties and dilution from future financing.